InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,815.03
(
0.61%
)
US TECH 100
19,700.00
(
-0.02%
)
Dow Jones
42,863.86
(
0.97%
)
Brent Oil
78.70
(
0.00%
)
Bitcoin
62,976.22
(
0.84%
)
Post# of 253351
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120561
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 186912

Monday, 02/02/2015 12:21:48 PM

Monday, February 02, 2015 12:21:48 PM

Post# of 253351
Re: HCV Japan

…BMY with a good but not great regimen sold $200M+ last quarter [in Japan] (I think EU sales of daclatasvir were minimal).

The breakdown of BMY’s 4Q14 HCV sales of $207M was approximately 2/3 in Japan (where Daklinza is sold with Sunvepra) and approximately 1/3 in the EU (where Daklinza is sold separately and used with Sovaldi).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up